Cancer Biomarkers Market: Current Progress, Growth Drivers, challenges, and Future Development

Cancer Biomarkers is growing rapidly as an industry due to growing preference for wireless connectivity among healthcare providers, increasing incidence of cancer worldwide, increasing use of cancer biomarkers in drug discovery & development and increasing R&D on cancer biomarkers are among the other factors.

Currently, Cancer Biomarkers Market is growing at a Compound Annual Growth Rate (CAGR) of 17.7% to reach USD 28.2 billion by 2026. Market growth is driven by the increasing use of cancer biomarkers in drug discovery and development, increasing research on cancer biomarkers, technological advancements, and the increasing global incidence of cancer.

Request for assumptions & how numbers were triangulated.

https://www.marketsandmarkets.com/requestsampleNew.asp?id=202 

Market Growth Drivers

• Rising technological advancements in the development of cancer biomarkers
• Increasing incidence of cancer worldwide
• Increasing use of cancer biomarkers in drug discovery & development

Market Growth Opportunities

• Increased recognition of personalized medicine
• Growing application areas of companion diagnostics
• Emerging economies

Market Challenges 

• Challenges associated with cancer biomarker validation.
• Shortage of skilled professionals

Restraints

• Technical issues related to sample collection and storage.
• High capital investments and extensive timelines for the development of cancer biomarkers

The prominent players operating in the Cancer Biomarkers Market are. 

F. Hoffmann-La Roche Ltd. (Switzerland), Thermo Fisher Scientific, Inc. (US), QIAGEN N.V. (Netherlands), Illumina, Inc. (US), Bio-Rad Laboratories, Inc. (US), Abbott Laboratories (US), bioMérieux SA (US)

F. Hoffmann-La Roche Ltd. held the leading position in the cancer biomarkers market in 2020. La Roche focuses on innovation to maintain its market share. It invests a significant amount of its revenue in R&D activities for this purpose. These investments are used to develop new and innovative products. The company’s major share comes from the US. With its high R&D capabilities, excellent balance sheet, and asset quality, the company is expected to witness a higher growth rate in the forecast period.

Thermo Fisher Scientific, Inc. held the second position in the cancer biomarkers market. The company focuses on innovation to maintain its market share. It invests a significant amount of its revenue in R&D activities for this purpose. These investments are used to develop new and innovative products. The company’s major share comes from the US. With its high R&D capabilities, excellent balance sheet, and asset quality, the company is expected to witness a higher growth rate in the forecast period.

Download an Illustrative Overview:

https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=202 

Competitive leadership mapping has been updated considering recent developments in the company evaluation matrix and company profiles section of the current edition of the market report.

Recent Developments

• In April 2021, F. Hoffmann-La Roche Ltd. (Switzerland), Launched Elecsys Anti-p53 immunoassay to aid the diagnosis of various cancer types.
• In December 2020, Thermo Fisher Scientific (US) received FDA approves NGS-based companion diagnostic for EGFR Exon20 insertion mutant non-small cell lung cancer tumor tissue.
• In April 2020, Qiagen N.V. (Netherlands) Launched therascreen BRAF test as a companion diagnostic to a BRAFTOVI (encorafenib) based regimen in metastatic colorectal cancer.

Content Source: 

https://www.prnewswire.com/news-releases/cancer-biomarkers-market-worth-28-2-billion-by-2026--exclusive-report-by-marketsandmarkets-301505629.html

https://www.globenewswire.com/en/news-release/2022/05/31/2453442/0/en/Cancer-Biomarkers-Market-worth-28-2-billion-by-2026-Report-by-MarketsandMarkets.html

Article source: https://article-realm.com/article/Finance/36429-Cancer-Biomarkers-Market-Current-Progress-Growth-Drivers-challenges-and-Future-Development.html